SubHero Banner
Text

Lyumjev® (insulin lispro-aabc) – Expanded indication

October 14, 2022 - The FDA approved Eli Lilly’s Lyumjev (insulin lispro-aabc), to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Download PDF